MetaCap

Atossa Therapeutics (ATOS) vs NewcelX (NCEL)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

NewcelX (NCEL) has outperformed Atossa Therapeutics (ATOS) over the past year, losing 22.3% versus a loss of 86.4%. Over five years, ATOS leads with a -95.3% price change compared with -99.7% for NCEL. Atossa Therapeutics is the larger company by market cap ($15.9 million vs $14.7 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ATOS-86.37%NCEL-22.32%
+57%-18%-93%
Nov 21, 20251 yearNov 20, 2026
ATOS-95.48%NCEL-99.68%
+5%-50%-105%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ATOS versus NCEL key metrics
MetricATOSNCEL
Share price$1.60$2.54
Market cap$15.92M$14.67M
1-day change-8.86%-5.58%
YTD return-81.98%+33.68%
1-year return-86.37%-22.32%
5-year return-95.34%-99.65%
P/E ratio (TTM)—4.88
EPS (TTM)$-3.92$0.52
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Net income (latest FY)$-34.77M$-8.30M
52-week high$14.85$5.12
52-week low$1.59$1.83
Distance from 52-week high-89.26%-50.39%
Analyst consensusstrong_buynone
Avg. price target upside+1091.22%+805.51%
Average volume68.00K13.34K
Shares outstanding9.98M5.78M
Employees169
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • NCEL has outperformed ATOS by 64.0 percentage points over the past year.

About Atossa Therapeutics

ATOS stock →

Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines in areas of significant unmet medical need in oncology in the United States. Its lead drug candidate is oral (Z)-endoxifen, a selective estrogen receptor modulator and selective estrogen receptor degrader currently in Phase 2 clinical development for the treatment and reduction of risk of breast cancer, as well as in other therapeutic areas.

Health Care · Biotechnology: Pharmaceutical Preparations · 16 employees

About NewcelX

NCEL stock →

NewcelX Ltd., a biopharmaceutical company, engages in developing transformative stem-cell-derived therapies for Diabetes. The company develops NCEL-101, a cellular therapy product based on enriched pancreatic islet-like clusters for the treatment of Type 1 diabetes and Type 2 insulin dependent diabetes; AstroRx, an off-the-shelf cryopreserved cell therapy product for the treatment of Amyotrophic Lateral Sclerosis and neurodegenerative indications; and Dual Orexin-Receptor Agonist (DOXA), a small molecules platform for the treatment of sleep disorders, Neurodegenerative/ neuroinflammation diseases, and Diabetes Associated Neurological Disorders.

Health Care · Biotechnology: Pharmaceutical Preparations · 9 employees

ATOS vs NCEL FAQ

Which is bigger, Atossa Therapeutics or NewcelX?

Atossa Therapeutics (ATOS) is larger, with a market capitalization of $15.92M compared with $14.67M for NewcelX (NCEL).

Which stock has performed better over the past year, ATOS or NCEL?

NCEL returned -22.32% over the past 12 months, compared with -86.37% for ATOS (price return, excluding dividends). Past performance does not predict future results.

Are Atossa Therapeutics and NewcelX in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons